FDA Approves IND for MDS Treatment APR-548

  In early October, the FDA approved an Investigational New Drug Application (IND) for APR-548, a potential treatment for patients with TP53 mutant myelodysplastic syndromes (MDS). According to a press release from…

Continue Reading FDA Approves IND for MDS Treatment APR-548